Monetta Financial Services Inc. Takes $1.50 Million Position in Illumina, Inc. $ILMN

Monetta Financial Services Inc. acquired a new position in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 8,500 shares of the life sciences company's stock, valued at approximately $1,495,000.

Other institutional investors have also recently bought and sold shares of the company. HighPoint Advisor Group LLC increased its stake in shares of Illumina by 3.7% in the fourth quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company's stock worth $291,000 after purchasing an additional 80 shares during the period. Elevation Wealth Partners LLC boosted its stake in Illumina by 52.5% during the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company's stock valued at $43,000 after purchasing an additional 84 shares during the period. Meeder Advisory Services Inc. grew its holdings in Illumina by 3.1% in the 1st quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company's stock valued at $348,000 after buying an additional 85 shares during the last quarter. Toronto Dominion Bank grew its holdings in Illumina by 0.3% in the 4th quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company's stock valued at $4,407,000 after buying an additional 92 shares during the last quarter. Finally, Panagora Asset Management Inc. increased its position in Illumina by 3.9% in the 4th quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company's stock worth $333,000 after buying an additional 96 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Evercore reaffirmed an "outperform" rating on shares of Illumina in a research report on Monday, July 6th. Canaccord Genuity Group increased their price target on shares of Illumina from $190.00 to $205.00 and gave the company a "hold" rating in a report on Monday, August 3rd. Royal Bank Of Canada raised their price target on shares of Illumina from $170.00 to $230.00 and gave the stock an "outperform" rating in a research report on Friday, July 31st. Stifel Nicolaus boosted their price objective on shares of Illumina from $155.00 to $225.00 and gave the stock a "buy" rating in a report on Friday, July 31st. Finally, Wall Street Zen raised shares of Illumina from a "hold" rating to a "buy" rating in a research report on Saturday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $188.40.

Illumina Price Performance

Shares of ILMN stock opened at $205.00 on Thursday. The stock's fifty day moving average is $185.90 and its 200-day moving average is $151.49. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The stock has a market capitalization of $30.95 billion, a PE ratio of 38.25, a PEG ratio of 2.65 and a beta of 1.45. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $207.00.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same period in the prior year, the business earned $1.19 earnings per share. Illumina's quarterly revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts expect that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Insider Transactions at Illumina

In other news, CAO Scott D. Ericksen sold 1,500 shares of Illumina stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $150.10, for a total value of $225,150.00. Following the completion of the sale, the chief accounting officer directly owned 14,946 shares of the company's stock, valued at approximately $2,243,394.60. This trade represents a 9.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the business's stock in a transaction on Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the sale, the senior vice president owned 21,259 shares of the company's stock, valued at approximately $3,456,500.81. The trade was a 3.55% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,415,351 shares of company stock valued at $255,966,311 over the last 90 days. 2.90% of the stock is currently owned by corporate insiders.

About Illumina

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source